UNSPSC 51351521: Anagestone acetate

This classification denotes a therapeutic progestin with the molecular formula C24H36O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GNT396G9QT, chemically known as pregn-4-en-20-one, 17-hydroxy-6alpha-methyl-, acetate (8ci) but more generally known as anagestone acetate, which bears US NIH Compound Identifier 18443. European Medicines Agency schedules Anagestone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00522MIG.

Most nations, for tariff and trade purposes, schedule anagestone acetate under HS 29372300 and SITC 54153. As of Q4 2014, ANAGESTONE ACETATE remains US FDA's Preferred Term for this commodity. Anagestone acetate bears US NLM identifiers UMLS ID C2698107 and NCI Concept Code C76302. SMILES: C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CCCC4)C.

UNSPSC 51351521 Anagestone acetate is a Commodity code that captures pharmaceutical products distributed through state and local government health and human services systems. In practice, state and local procurement under this code buys generic pharmaceuticals and over-the-counter products—often as part of broader multi-product procurement vehicles—through established wholesale distribution networks rather than direct-to-agency sales. The issuing bodies are primarily state cooperative purchasing alliances and state health departments that aggregate demand across multiple member agencies, school districts, and local government facilities. Individual jurisdictions do not typically solicit anagestone acetate in isolation; instead, they participate in statewide or multi-state cooperative contracts that establish pricing and supply terms for entire pharmaceutical product categories.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with participation from Oregon and other member states. The RFP, due March 26, 2026, targets pharmaceutical manufacturers willing to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC) with National Drug Codes (NDC), SKUs, and pricing in flat-price, net-price, or WAC-minus formats. Vendors must certify cGMP and Drug Supply Chain Security Act (DSCSA) compliance, maintain relationships with at least two of the three wholesalers, and carry $5 million commercial general liability and $2 million network security liability insurance. The contract term is two years for new responders with optional extensions, or alignment with existing expiration dates through June 30, 2028 for incumbents; award values are not disclosed, but vendors must pay a 3 percent administrative fee and accept performance penalties of $200 to $1,500 per violation.